StockUS listing USBOLDNASDAQHealthcareCapital Destroyer

Boundless Bio, Inc. Common Stock(BOLD) Stock Analysis | Healthcare

USD --+0.00%
Reward44Moderate
Risk44Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 54.78M
Reward Ratingⓘ44 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ44 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BOLD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Boundless Bio, Inc. Common Stock?

, a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.

AI Brief Pro

The brief on Boundless Bio, Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Boundless Bio, Inc. Common Stock?

, a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 54.78M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.458
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
118,300 shares
$54k
18312,356 shares
$736k
3-6months
0
12,975 shares
$7k
6-9months
0
0
9-12months
0
0